Yousif Capital Management LLC, a prominent institutional investor, has recently reduced its stake in Glaukos Co. by 11.5% in the first quarter of the year, according to a filing with the Securities and Exchange Commission (SEC) dated August 2, 2023. The purpose behind this move remains undisclosed, leaving investors and market analysts curious about the motivation behind this decision.
As per the filing, Yousif Capital Management LLC held 26,891 shares of Glaukos Co., which represents approximately 0.06% of the company’s total worth. The investment firm sold 3,505 shares during the specified period, resulting in an adjusted portfolio value of $1,347,000 at the end of the quarter.
Glaukos Corporation is a renowned ophthalmic medical technology and pharmaceutical company known for its innovation in developing novel therapies for treating glaucoma, corneal disorders, and retinal diseases. Among its notable products are iStent, iStent inject, and iStent inject W micro-bypass stents that enhance aqueous humor outflow. These stents are inserted during cataract surgeries to effectively address mild-to-moderate open-angle glaucoma.
On Wednesday morning, Glaukos stock opened at $76.66 per share. With a market capitalization of $3.70 billion and a P/E ratio standing at -26.25 along with a beta of 1.28—indicating that it tends to move somewhat more than its underlying index—the company’s financial statistics demonstrate its steady growth potential despite certain ongoing challenges.
Looking back on Glaukos Co.’s recent performance in the stock market reveals both positive trends and noteworthy fluctuations. Over the past year alone, its shares have observed significant movement from a low point of $40.45 up to an impressive high value of $80.28—an upward trajectory signaling investor confidence and market optimism. This consistent growth can be attributed to Glaukos’ focus on catering to unmet medical needs and its ability to leverage technology advancements in the ophthalmic field.
Moreover, Glaukos Co. possesses a favorable debt-to-equity ratio of 0.70, indicating a stable financial position and a relatively balanced leverage structure. Furthermore, the company maintains a quick ratio of 6.02 and a current ratio of 6.67, reinforcing its ability to meet short-term obligations and navigate uncertainties inherent in the healthcare industry.
Technical analysis demonstrates that Glaukos stock has performed decently considering its various moving averages. The 50-day simple moving average stands at $68.67, showcasing steady growth over recent periods, while the longer-term 200-day simple moving average is projected at $56.75—highlighting an even more substantial increase in value over time.
As we delve deeper into the nuances of Glaukos Co., it becomes evident that despite periodic market volatility affecting medical instrument companies, this innovative organization stands strong amidst industry competition. With its dedicated focus on developing groundbreaking therapies for debilitating eye conditions such as glaucoma, corneal disorders, and retinal diseases, Glaukos remains poised to capitalize on growing global demand for effective treatment options.
While Yousif Capital Management LLC’s decision to reduce its stake in Glaukos raises intrigue within investment circles, there may be distinct factors driving this choice beyond what meets the eye. Investors will undoubtedly keep a close watch on further developments within both Yousif Capital Management LLC’s portfolio adjustments and Glaukos Co.’s future outlook, as they seek to uncover underlying motivations and assess their potential impact on investors’ decisions going forward.
Disclaimer: The information provided in this article is based on publicly available data as of August 2, 2023. Any opinions expressed are solely those of the author and do not constitute financial advice or investment recommendations.
[bs_slider_forecast ticker=”GKOS”]
Institutional Investors Display Interest in Glaukos Corporation; Insiders Sell Shares
Glaukos Corporation, a leading ophthalmic medical technology and pharmaceutical company, has seen numerous institutional investors increase or decrease their stakes in the company. Connor Clark & Lunn Investment Management Ltd. raised its position in Glaukos shares by an impressive 103.7% during the fourth quarter, purchasing an additional 22,381 shares and bringing its total ownership to 43,964 shares worth $1.92 million.
Another notable investor, Mirae Asset Global Investments Co. Ltd., increased its stake in Glaukos by 1.8% during the same period, acquiring an additional 393 shares and bringing its total ownership to 21,960 shares valued at $959,000. State of New Jersey Common Pension Fund D also significantly raised its stake in Glaukos by 5.6%, adding 2,601 more shares to reach a total of 49,100 shares worth $2.14 million.
Granite Investment Partners LLC additionally increased its position in Glaukos by an impressive 23.5%, acquiring an additional 11,339 shares and owning a total of 59,524 shares worth $2.6 million as of the fourth quarter. Commonwealth Equity Services LLC joined this trend by raising its holdings in Glaukos by 23.3%, adding another 1,031 shares to reach a total of 5,448 shares valued at $237,000.
Overall, institutional investors and hedge funds currently own around 97.5% of Glaukos’ stock – a significant proportion that reflects their confidence and interest in the company’s growth potential.
In other news related to Glaukos Corporation’s stock activity, COO Joseph E. Gilliam recently sold a considerable number of shares on July 12th for approximately $197k while CEO Thomas William Burns sold some of his holdings on May 16th for approximately $222k.
These transactions were both disclosed in official filings with the Securities & Exchange Commission (SEC). The sale by Gilliam involved 2,700 shares at an average price of $73.09 each, leaving Gilliam with 120,484 shares valued at $8.81 million. Burns’ sale consisted of 3,704 shares at an average price of $60.01 per share, leaving him with a remaining 673,963 shares valued at $40.44 million.
Notably, insiders have sold a total of 179,706 shares of Glaukos stock over the last ninety days, amounting to a value of $12.98 million. Currently, insiders own approximately 7.8% of the company’s stock.
Glaukos Corporation primarily focuses on developing novel therapies for treating glaucoma, corneal disorders, and retinal diseases in ophthalmology. One noteworthy product offering from Glaukos is its iStent technology – specifically iStent inject and iStent inject W micro-bypass stents – which enhance aqueous humor outflow by being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma.
On May 3rd, Glaukos reported its quarterly earnings results for Q1 2023. Despite a negative return on equity of 21.2% and negative net margin of 48.15%, the medical instruments supplier managed to beat consensus estimates with earnings per share (EPS) coming in at ($0.59), surpassing the estimated ($0.61) by $0.02.
The company generated revenue amounting to $73.9 million throughout the quarter – a promising increase compared to analysts’ expectations of $67.74 million – translating to a year-on-year growth rate of 9.2%. While these figures suggest positive progress for Glaukos in terms of revenue generation and financial performance despite its negative metrics, analysts anticipate the company to post a projected EPS of -2.27 for the current year.
Recently, research analysts have issued various reports on Glaukos Corporation. StockNews.com downgraded Glaukos from a “hold” to a “sell” rating in a research report published on July 22nd. Citigroup, on the other hand, increased its price target on Glaukos shares from $59 to $85 in early July. Meanwhile, 888 has maintained its rating on the stock since May 4th.
BTIG Research also raised its target price for Glaukos shares from $67 to $83 in mid-July, expressing optimism about the company’s future prospects based on its performance and potential. Lastly, Stifel Nicolaus increased its price target for Glaukos shares from $65 to $77 at the end of June.
Despite these varying ratings and price targets among analysts, with some recommending a sell or hold while others suggest buying opportunities, Bloomberg indicates that there is an overall consensus rating of “Hold” for Glaukos Corporation stock with an average price target of $73.22.
In conclusion, institutional investors have displayed significant interest in Glaukos Corporation by either increasing or decreasing their stakes in the company. The transactions made
